stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) Net income
Teva Pharmaceutical Industries Ltd.'s net income for fiscal 2025 was $1.4B, compared with −$2.0B in fiscal 2024. Over the twelve months to 30 September 2026 it was $508.0M. Over the past ten years it has ranged from −$16.4B (fiscal 2017) to $1.6B (fiscal 2015); the current reading is higher than 91% of that period. Teva Pharmaceutical Industries Ltd. ranks 7th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.4B | — |
| FY2024 | −$2.0B | — |
| FY2023 | −$615.0M | — |
| FY2022 | −$2.5B | — |
| FY2021 | $456.0M | — |
| FY2020 | −$4.1B | — |
| FY2019 | −$1.0B | — |
| FY2018 | −$2.5B | — |
| FY2017 | −$16.4B | — |
| FY2016 | $311.0M | (80.53%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $233.0M | — |
| Jun 2026 | −$575.0M | — |
| Mar 2026 | $369.0M | (23.28%) |
| Dec 2025 | $481.0M | 10.83% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $3.2B |
| HLN Haleon PLC Sponsored ADR compare | $3.1B |
| ZTS Zoetis Inc. compare | $2.6B |
| UTHR United Therapeutics Corporation compare | $1.2B |
| NBIX Neurocrine Biosciences, Inc. compare | $702.5M |
| TEVA Teva Pharmaceutical Industries Ltd. | $508.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| ELAN Elanco Animal Health Incorporated compare | −$199.0M |
| VTRS Viatris Inc. compare | −$607.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TEVA
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement